- Home
- GAM vs PCRX Comparison
GAM vs PCRX Comparison
Compare GAM & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- PCRX
- Stock Information
- Founded
- GAM 1927
- PCRX 2006
- Country
- GAM United States
- PCRX United States
- Employees
- GAM N/A
- PCRX N/A
- Industry
- GAM Investment Managers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GAM Finance
- PCRX Health Care
- Exchange
- GAM Nasdaq
- PCRX Nasdaq
- Market Cap
- GAM 1.2B
- PCRX 1.2B
- IPO Year
- GAM N/A
- PCRX 2011
- Fundamental
- Price
- GAM $51.74
- PCRX $25.12
- Analyst Decision
- GAM
- PCRX Buy
- Analyst Count
- GAM 0
- PCRX 9
- Target Price
- GAM N/A
- PCRX $29.89
- AVG Volume (30 Days)
- GAM 20.1K
- PCRX 745.0K
- Earning Date
- GAM 01-01-0001
- PCRX 05-08-2025
- Dividend Yield
- GAM 5.74%
- PCRX N/A
- EPS Growth
- GAM N/A
- PCRX N/A
- EPS
- GAM 11.67
- PCRX N/A
- Revenue
- GAM N/A
- PCRX $702,772,000.00
- Revenue This Year
- GAM N/A
- PCRX $9.48
- Revenue Next Year
- GAM N/A
- PCRX $11.31
- P/E Ratio
- GAM $3.95
- PCRX N/A
- Revenue Growth
- GAM N/A
- PCRX 3.08
- 52 Week Low
- GAM $37.32
- PCRX $11.16
- 52 Week High
- GAM $46.48
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- GAM 60.94
- PCRX 48.10
- Support Level
- GAM $51.08
- PCRX $25.08
- Resistance Level
- GAM $52.19
- PCRX $27.34
- Average True Range (ATR)
- GAM 0.76
- PCRX 1.16
- MACD
- GAM 0.24
- PCRX -0.18
- Stochastic Oscillator
- GAM 89.91
- PCRX 48.85
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.